Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Roche Global Development
Patients who have received anti-CMV therapy with intravenous ganciclovir for at least 4 weeks that resulted in stable retinitis are randomized to receive one of three doses of oral ganciclovir or intravenous ganciclovir for 26 weeks of maintenance.
Age
13–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Concurrent Medication:
Allowed:
Topical and ophthalmic nucleoside analogues.
Patients must have:
HIV positive.
No more than two episodes of CMV retinitis progression (relapse resulting in reinduction with intravenous anti-CMV therapy) since the original retinitis diagnosis.
Currently stable retinitis.
Prior Medication:
Allowed:
Foscarnet prior to the 4 weeks of intravenous induction therapy.
You may not be if
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
Persistent or clinically significant diarrhea, nausea, or abdominal pain.
Severe odynophagia.
Other gastrointestinal (GI) symptoms or uncontrolled GI disease.
Active CMV disease of the GI tract (e.g., CMV colitis, CMV esophagitis).
Ocular media opacities (corneal, lenticular, or vitreal) that prevent ophthalmologic retinal assessments.
Dementia, decreased mentation, or other encephalopathic signs and symptoms that would preclude informed consent or study compliance.
Concurrent Medication:
Excluded:
Acyclovir sodium (Zovirax) by any route other than topical.
